Imipramine Hcl Tablets

Imipramine Hcl Tablets

Form: Tablets

Strength: 10 mg, 25 mg, 50 mg

Reference Brands: Tofranil®(EU & US)

Category: Antipsychotropic Drugs

In the United States, Imipramine HCl tablets are FDA-approved for the treatment of major depressive disorder (MDD) and nocturnal enuresis in children. As a tricyclic antidepressant (TCA), it carries a Boxed Warning about the increased risk of suicidal thoughts in young adults. U.S. regulations require GMP-compliant manufacturing, proper labeling, and bioequivalence data for generics. Periodic safety monitoring and REMS (Risk Evaluation and Mitigation Strategy) may apply based on evolving risk data. In the European Union, Imipramine is available through national marketing authorizations. Regulatory standards require Risk Management Plans (RMPs), pharmacovigilance compliance, and updated labeling based on EMA safety assessments. For dossier-ready Imipramine tablet supplies, visit Pharmatradz.com.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Risperidone Long-Acting Injection

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes

Form: Long-Acting Injection

Reference Brands: Risperdal Consta(US &EU)

View Details Get Enquiry
Zuclopenthixol ong-acting IM Injection (Depot)

Strength: 200 mg/mL, 500 mg/mL

Form: Long-acting IM Injection (Depot)

Reference Brands: Clopixol Depot®(US)

View Details Get Enquiry
Zuclopenthixol Short-acting Intramuscular Injection

Strength: 50 mg/mL

Form: Short-acting Intramuscular Injection

Reference Brands: Clopixol-Acuphase®

View Details Get Enquiry
Zuclopenthixol tablets

Strength: 10 mg, 25 mg, 40 mg

Form: Oral Tablets

Reference Brands: Clopixol®(EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more